Pulmonary Essay

Lymphangioleiomyomatosis (LAM) Pulmonary diseases and conditions have been present since the lungs were discovered by ancient doctors. From tuberculosis to COPD, our lungs are highly susceptible to illness. What causes these illnesses? Oftentimes, it’s environmental. The infectious particles in the air we breathe or materials we purposely inhale, ie. cigarettes, that make it through our bodies’ filters cause many of these problems. But for diseases like LAM, the cause is genetic. LAM is a rare lung

Etiology A lung disease that makes it difficult to breathe and causes the air passage way to the lungs to become inflamed is called, Chronic Obstructive Pulmonary Disease (COPD). For many years, people have been plagued with this disease, mostly contributed to cigarette smoking, tobacco smoke or air pollution. COPD is the third leading cause of death in the United States Other diseases that can contribute to the disease is asthma, emphysema and bronchitis. This respiratory disease makes it hard

examination, CNP notice clubbing of his fingers, use accessory muscles for respiration, wheezing in the lungs, and hyperresonance on percussion of the lungs, and also pulmonary function studies show an FEV1 of 58%. These all symptoms and history represented here most strongly indicate the probability of chronic obstructive pulmonary disease (COPD). COPD is a respiratory disease categorized by chronic airway inflammation, a decrease in lung function over time, and gradual damage in quality of life

Chronic obstructive pulmonary disease [copd] It means a group of lung diseases which plug airflow when a person exhales. This makes breathing process increasingly difficult. COPD includes Chronic bronchitis, emphysema, and asthmatic bronchitis . Each of these cases causes ill health and death worldwide.[1] COPD is not a new condition. Previously, physicians used different expressions to describe what we now describe as COPD. Swiss physician Bonet (1679) referred to ‘voluminous lungs’ , Italian

Chronic Obstructive Pulmonary Disease (COPD) is progressively common amongst patients within the United States. The disease is more common in patients with a long smoking history. Inflammatory changes are largely responsible for the development and symptoms of COPD. COPD is typically managed according to classification of severity based on the GOLD guidelines. Anoro Ellipta is a new once daily FDA approved drug. It is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting b2-agonist

Chronic obstructive pulmonary disease (COPD) is one of the most common types of lung disease that includes emphysema and chronic bronchitis. This abnormal lung inflammatory response is characterized by a persistent airflow obstruction, which is not fully reversible (Lee, Kim, & Tagmazyan, 2013). COPD is a major public health problem as it causes major disability, morbidity, and mortality. Moreover, economic consequences of COPD are substantial. In 2010, the estimated total societal cost of COPD

Based on the information provided; the three differential diagnosis that are being considered include; chronic obstructive pulmonary disease (COPD), bronchitis and community acquired pneumonia (CAP) (Papadakis, McPhee, & Rabow, 2015). COPD Symptoms of COPD often begin in middle age and is commonly caused by years of smoking. COPD is progressive, irreversible and made up of chronic bronchitis and emphysema (Goolsby & Grubbs, 2011). Symptoms include; chronic productive cough for three consecutive

Chronic Obstructive Pulmonary Disease 1.2.1 Definitions and Terminology --------------------------- There are no universally accepted terminology or definition for the group of conditions characterised by airways obstruction that is completely reversible (Snider, 1996). There are several problems that have to be considered. The first results from the use of the term ‘chronic obstructive pulmonary disease’ (COPD), which is considered inaccurate

and restoring their health is a required nursing skill that most often results in a positive outcome, enhancing the patient 's quality of life” (Lewis et al., 2014, p.52). The intent of this analysis is to educate patients with chronic obstructive pulmonary disease on means that can enhance their quality of life and avert the progression of their disease. More specifically, it will focus on the aspect of teaching Mrs. N, a patient, how to effectively handle certain symptoms experienced with techniques

understand COPD, we as nurses must develop an understanding of the structural and functional changes in cells and tissues caused by infectious agents. COPD is characterised by chronic inflammation of the airways, including gas exchange surfaces and pulmonary blood vessels. The pathogenesis of COPD is quite complex and involves many mechanisms. The defining features of COPD are irreversible airflow limitation during forced exhalation and obstruction caused by mucous hypersecreation, mucosal oedema and